PCVX
HealthcareVaxcyte, Inc.
$46.03
$-0.43 (-0.93%)
Jan 5, 2026
Price History (1Y)
Analysis
Vaxcyte, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $6.03 billion. The company has a significant employee base with 414 staff members. The company's financial health indicates a negative profitability profile, with gross margin, operating margin, and profit margin all at 0.0%. This is reflected in its net income and EBITDA, which are -$657,201,024 and -$799,798,016 respectively. The company's returns on equity and assets are also negative, standing at -20.8% and -15.1%, respectively. On the other hand, the balance sheet shows a relatively healthy cash position with $1.71 billion in cash and only $84.44 million in debt. The valuation context of Vaxcyte, Inc. is marked by a forward P/E ratio of -7.40 and an EV/EBITDA ratio of -5.57, indicating a potentially volatile market perception of the company's value. The price to book ratio stands at 2.07, providing some context for the valuation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Visit website →Key Statistics
- Market Cap
- $6.03B
- P/E Ratio
- N/A
- 52-Week High
- $93.77
- 52-Week Low
- $27.66
- Avg Volume
- 1.48M
- Beta
- 1.34
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 414